Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

452
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
452
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

In Vitro Characterization of Cannabidiol As a Possible Adjuvant for Long-Lasting Local Anesthesia.

Anesthesia and analgesia·2026
Same author

The Excelsatoxin A-Receptor TMEM233 Modulates Nav1.8.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

UVA Light Triggers Activation of TRPV1 and TRPA1 by Staurosporine and Midostaurin.

International journal of molecular sciences·2026
Same author

TRPV2 Regulates Function of Human Neutrophil Granulocytes.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Determinants for Activation of the Ion Channel TRPV3 by Weak Acids.

International journal of molecular sciences·2025
Same author

Weak Acids as Endogenous Inhibitors of the Proton-Activated Chloride Channel.

Cells·2025
Same journal

RETRACTED: Bakshi et al. Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways. <i>Cells</i> 2022, <i>11</i>, 1502.

Cells·2026
Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026
Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026
Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026
查看所有相关文章

相关实验视频

Updated: Jan 13, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
07:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

21.8K

特拉尼拉斯特不抑制TRPV2的发生.

Tabea C Fricke1,2, Nele Stein1, Christine Herzog1

  • 1Department of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.

Cells
|January 9, 2026
PubMed
概括
此摘要是机器生成的。

特拉尼拉斯特不会直接抑制TRPV2通道. 相反,它通过减少活性氧物种 (ROS) 来间接降低TRPV2激活,影响其作为特定TRPV2抑制剂的使用.

关键词:
在 TRPV2 中.道药理学 道药理学离子通道调制 离子通道调制反应性氧物种 (ROS) 是一种反应性氧物种.这里是tranilastlast的位置.

更多相关视频

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.6K
Controllable Ion Channel Expression through Inducible Transient Transfection
10:00

Controllable Ion Channel Expression through Inducible Transient Transfection

Published on: February 17, 2017

9.8K

相关实验视频

Last Updated: Jan 13, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
07:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

21.8K
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.6K
Controllable Ion Channel Expression through Inducible Transient Transfection
10:00

Controllable Ion Channel Expression through Inducible Transient Transfection

Published on: February 17, 2017

9.8K

科学领域:

  • 离子通道生理学 离子通道生理学
  • 药理学 药理学是指药理学的学科.
  • 细胞信号传递 细胞信号传递

背景情况:

  • 临时受体潜在化物2 (TRPV2) 通道涉及各种生理和病理功能.
  • 特拉尼拉斯特通常被认为是TRPV2的特定抑制剂,但其潜在机制尚不清楚.

研究的目的:

  • 调查tranilast是否直接抑制TRPV2通道活动.
  • 阐明特拉尼拉斯与TRPV2.2相互作用的分子机制.

主要方法:

  • 在表达鼠TRPV2.2的HEK293细胞中进行全细胞电生理学和成像.
  • 在老鼠基白血病 (RBL) 细胞中进行细胞检测,包括TRPV2-淘汰赛变体.
  • 在CRISPR/Cas9基因编辑中进行TRPV2淘汰赛.

主要成果:

  • 特拉尼拉斯特并没有抑制TRPV2电流或标准激动剂诱导的流量.
  • 特拉尼拉斯特减少了氧化诱导的TRPV2激活,这表明它干扰了氧化还原信号.
  • 特拉尼拉斯降低了胺T诱导的TRPA1激活和电压关闭的Na+通道电流.
  • 细胞活性在野生型和TRPV2-淘汰赛RBL细胞中都被tranilast降低,在淘汰赛细胞中影响较小.

结论:

  • 特拉尼拉斯特不会直接抑制TRPV2通道.
  • 特拉尼拉斯特通过减少活性氧物种 (ROS) 来间接抑制TRPV2激活.
  • 这一发现需要在针对TRPV2.2的研究中重新评估tranilast的作用.